MedWorm: Radioiodine Therapy

Effects of drugs on the efficacy of radioiodine (131I) therapy in hyperthyroid patients

Articles of Archives of Medical Science - TERMEDIA publishing house — Tue, 09 Mar 2010 16:04:44 +0100

The treatment of hyperthyroidism is targeted at reducing the production of thyroid hormones by inhibiting their synthesis or suppressing their release, as well as by controlling their influence on peripheral tissue (conservative therapy, medical treatment). Radical treatment includes surgical intervention to reduce the volume of thyroid tissue or damage of the mechanisms of thyroid hormone synthesis by radioiodine (131I) administration. Radioiodine ( 131I) is a reactor radionuclide, produced as a result of uranium decomposition and emission of β and γ radiation. The therapeutic effects of the isotope are obtained by the emission of β radiation. In the paper, the effects of administered drugs (antithyroid, glucocorticosteroids, lithium carbonate, inorganic iodine, β-bloc...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Pulmonary Fibrosis Following Radioiodine Therapy of Pulmonary Metastases from Differentiated Thyroid Carcinoma

Thyroid — Mon, 01 Mar 2010 04:53:36 +0100

Thyroid Mar 2010, Vol. 20, No. 3: 337-340. (Source: Thyroid)

Approach to the thyroid cancer patient with extracervical metastases.

The Journal of Clinical Endocrinology and Metabolism — Mon, 01 Mar 2010 00:00:00 +0100

Authors: Haugen BR, Kane MA Patients with distant, or extracervical, metastases from differentiated thyroid cancer require multimodality diagnostic, therapeutic, and monitoring approaches. Whereas cure is the initial goal, especially in those with small, radioiodine-avid pulmonary metastases, improved survival and management of symptoms become the primary objective in many patients with persistent disease, especially those with bone metastases. Levothyroxine therapy with suppression of serum TSH is a primary therapy in all patients with advanced differentiated thyroid cancer, and this therapy has been shown to improve overall survival and slow disease progression. Radioiodine is also an important systemic therapy for those patients with radioiodine-avid disease who respond to this targ...

[Nuclear medical inpatient treatment in Germany. Analysis of the structured quality reports 2004 to 2008.]

Nuklearmedizin — Mon, 01 Mar 2010 00:00:00 +0100

Conclusions: In analogy to the observations from Europe after introduction of an iodine prophylaxis the improved iodine supply in Germany has led to a decline of the radioiodine therapy due to hyperthyroidism. PMID: 20198278 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging — Thu, 25 Feb 2010 20:27:20 +0100

Content Type Journal ArticleCategory Focus onDOI 10.1007/s00259-010-1398-0Authors Massimo Salvatori, Catholic University of Sacred Heart Nuclear Medicine Institute, Policlinico Universitario “A.Gemelli” Rome ItalyMarkus Luster, University of Ulm Department of Nuclear Medicine Ulm Germany Journal European Journal of Nuclear Medicine and Molecular ImagingOnline ISSN 1619-7089Print ISSN 1619-7070 (Source: European Journal of Nuclear Medicine and Molecular Imaging)

Update on Recent Developments in the Therapy of Differentiated Thyroid Cancer

Seminars in Nuclear Medicine — Fri, 29 Jan 2010 15:14:19 +0100

This article deals with the current options of optimal therapy regimens in differentiated thyroid carcinoma. (Source: Seminars in Nuclear Medicine)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Nationwide trends in surgery and radioiodine treatment for benign thyroid disease during iodization of salt.

European Journal of Endocrinology — Mon, 18 Jan 2010 00:00:00 +0100

Conclusions: Iodization seemed to be associated with a temporary increase in the utilization rate of surgery and radioiodine therapy in the region of prior moderate ID, probably as a result of treatment of iodine-induced hyperthyroidism, but the rates ended up lower than before iodization. PMID: 20083558 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)

Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.

Nuklearmedizin — Wed, 13 Jan 2010 00:00:00 +0100

CONCLUSION: (124)I PET(/CT) dosimetry also corroborates the low ODpAs to the salivary glands. A voxel-based calculation taking into account the nonuniform activity distributions in the glands is necessary to possibly explain the radiation-induced salivary gland damage. PMID: 20069293 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging — Tue, 12 Jan 2010 18:17:40 +0100

Conclusion 124I PET(/CT) dosimetry also corroborates the low ODpAs to the salivary glands. A voxel-based calculation taking into account the nonuniform activity distributions in the glands is necessary to possibly explain the radiation-induced salivary gland damage. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-009-1351-2Authors Walter Jentzen, Universität Duisburg-Essen Klinik für Nuklearmedizin Hufelandstrasse 55 45122 Essen GermanyRobert F. Hobbs, Johns Hopkins University Department of Radiology, School of Medicine Baltimore MD USAAlexander Stahl, Universität Duisburg-Essen Klinik für Nuklearmedizin Hufelandstrasse 55 45122 Essen GermanyJochen Knust, Universität Duisburg-Essen Klinik für Nuklearmedizin Hufelandstrasse 55 45122 Esse...

The influence of thiamazole, lithium carbonate, or prednisone administration on the efficacy of radioiodine treatment ((131)I) in hyperthyroid patients.

Endokrynologia Polska — Fri, 01 Jan 2010 00:00:00 +0100

Conclusions: The present results indicate the necessity of careful analysis of administered drugs in hyperthyroid patients while qualifying them to (131)I therapy. The initial concentration of TSH has no effect on the efficacy of radioiodine therapy in cases where absorbed doses are regarded to be ablative. (Pol J Endocrinol 2010; 61 (1): 56-61). PMID: 20205105 [PubMed - in process] (Source: Endokrynologia Polska)

Excellent Prognosis of Patients with Solitary T1N0M0 Papillary Thyroid Carcinoma Who Underwent Thyroidectomy and Elective Lymph Node Dissection Without Radioiodine Therapy

World Journal of Surgery — Wed, 30 Dec 2009 06:52:58 +0100

Conclusions These findings suggest that solitary T1N0M0 patients have an excellent prognosis when they undergo thyroidectomy and elective lymph node dissection without radioiodine therapy. Regarding the extent of thyroidectomy, hemithyroidectomy is adequate for these patients, if a 1% risk of recurrence to the remnant thyroid is accepted. Content Type Journal ArticleDOI 10.1007/s00268-009-0356-0Authors Yasuhiro Ito, Kuma Hospital Department of Surgery 8-2-35, Shimoyamate-dori, Chuo-ku Kobe City 650-0011 JapanHiroo Masuoka, Kuma Hospital Department of Surgery 8-2-35, Shimoyamate-dori, Chuo-ku Kobe City 650-0011 JapanMitsuhiro Fukushima, Kuma Hospital Department of Surgery 8-2-35, Shimoyamate-dori, Chuo-ku Kobe City 650-0011 JapanHiroyuki Inoue, Kuma Hospital Department...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Effects and safety of iopanoic acid in cats

Advances in Small Animal Medicine and Surgery — Tue, 01 Dec 2009 00:00:00 +0100

Methimazole blocks the synthesis of thyroid hormones and is the mainstay of medical treatment for hyperthyroidism in cats. However, adverse effects occur in up to 18% of treated cats. The most common adverse effects are vomiting and anorexia, but more serious effects, such as facial excoriation, hepatotoxicity, and blood dyscrasias, occur in up to 10% of cases, requiring the discontinuation of the drug. Thyroidectomy or radioiodine therapy are the usual remaining options for cats. (Source: Advances in Small Animal Medicine and Surgery)

Long-Term Outcome of Differentiated Thyroid Carcinoma: Experience in a Developing Country

World Journal of Surgery — Sun, 29 Nov 2009 09:38:23 +0100

Conclusions Advance stage at presentation and proportionately high rates of FTC and PDTC contribute to poor outcome of DTC in developing countries. Despite dismal outcome, total thyroidectomy seems to prevent thyroid bed recurrence in surviving patients. Content Type Journal ArticleDOI 10.1007/s00268-009-0293-yAuthors Panchagan Rama Kant Bhargav, Sanjay Gandhi Postgraduate Institute of Medical Sciences Department of Endocrine Surgery Raebareli Road Lucknow 226 014 IndiaAnjali Mishra, Sanjay Gandhi Postgraduate Institute of Medical Sciences Department of Endocrine Surgery Raebareli Road Lucknow 226 014 IndiaGaurav Agarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences Department of Endocrine Surgery Raebareli Road Lucknow 226 014 IndiaAmit Agarwal, Sanjay Gan...

Radioiodine concentration by the thymus in differentiated thyroid carcinoma: report of five cases

Arquivos Brasileiros de Endocrinologia e Metabologia — Fri, 27 Nov 2009 14:12:00 +0100

The radioactive iodine has been used with great value as a diagnostic and therapeutic method in patients with differentiated thyroid carcinoma previously submitted to total thyroidectomy. False-positive whole-body scans may occur due to misinterpretation of the physiologic distribution of the radioisotope or lack of knowledge on the existence of other pathologies that could eventually present radioiodine uptake. Thymic uptake is an uncommon cause of false-positive whole-body scan, and the mechanism through which it occurs is not completely understood. The present paper reports five cases of patients with differentiated thyroid cancer who presented a mediastinum uptake of radioiodine in a whole-body scan during follow-up. The patients had either histological or radiological confirmation of ...

Targeted therapies in thyroid cancer

Targeted Oncology — Tue, 10 Nov 2009 18:08:28 +0100

Abstract Differentiated thyroid carcinoma is the most frequent neoplasm of the endocrine system. Although thyroid cancer usually has an excellent prognosis, no therapeutic options are available for patients that develop metastases and are or became resistant to radioiodine therapy. The deeper knowledge of molecular aberrations that characterize tumor growth has provided novel targets in cancer therapy. Several proteins have been implicated as having a crucial role in the carcinogenesis of differentiated thyroid cancer, such as those involved in RET/PTC-RAS-RAF-MAPK pathway. Moreover, vascular aberrations and angiogenesis equilibrium have also been related to tumor growth. The development of new, targeted therapies and their encouraging initial results have opened a hopeful...

Radioiodine, Smoking Linked to Eye Disease in Graves' Hyperthyroidism

Medscape Pharmacist Headlines — Mon, 09 Nov 2009 16:57:34 +0100

Radioiodine therapy and smoking increase the risk of developing thyroid-associated ophthalmopathy in patients with Graves' hyperthyroidism, say researchers from Sweden in the October issue of The Journal of Clinical Endocrinology & Metabolism. Reuters Health Information (Source: Medscape Pharmacist Headlines)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Outcome After High-Dose Radioiodine Therapy for Advanced Differentiated Thyroid Carcinoma in Childhood

Endocrine Research — Sun, 01 Nov 2009 00:00:00 +0100

(Source: Endocrine Research)

Takotsubo cardiomyopathy following radioiodine therapy for toxic multinodular goitre.

The Netherlands Journal of Medicine — Sun, 01 Nov 2009 00:00:00 +0100

We report on a 73-year-old man with a toxic multinodular goitre, which was treated with radioiodine therapy (I-131) without pretreatment with an antithyroid drug. Four weeks later he presented with rapidly progressive dyspnoea and a significant increase in free thyroxin. The electrocardiogram showed ST -segment elevation, and echocardiography demonstrated apical akinesia and a left ventricular ejection fraction of only 25%. However, direct coronary catheterisation showed no evidence of coronary artery disease. Left ventricular angiography showed apical ballooning consistent with the diagnosis of takotsubo cardiomyopathy. Following treatment of the cardiomyopathy and thyrotoxicosis, he experienced a complete recovery. To the best of our knowledge, this is the first report of a takotsubo car...

A case of thyroid storm following radioiodine therapy underlying usefulness of cardiac MRI.

European Journal of Internal Medicine — Wed, 30 Sep 2009 18:05:40 +0100

Authors: Thebault C, Leurent G, Potier J, Bedossa M, Bonnet F PMID: 19782905 [PubMed - in process] (Source: European Journal of Internal Medicine)

Targeted Radioiodine Therapy of Neuroblastoma Tumors following Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene.

Clinical Cancer Research — Mon, 28 Sep 2009 23:00:00 +0100

CONCLUSIONS: In conclusion, our data clearly show the high potential of novel pseudodendritic polymers for tumor-specific NIS gene delivery after systemic application, opening the prospect of targeted NIS-mediated radionuclide therapy of nonthyroidal tumors even in metastatic disease. (Clin Cancer Res 2009;15(19):6079-86). PMID: 19789324 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

[Subjective perception of radioactivity - no change post successful treatment with radioiodine]

Nuklearmedizin — Sat, 19 Sep 2009 12:38:06 +0100

CONCLUSION: Patients continue to view radioactivity as something negative despite treatment success following radioiodine therapy. Our results provide useful information for patient information by the nuclear medicine physician prior to a radioiodine therapy. PMID: 19322502 [PubMed - indexed for MEDLINE] (Source: Nuklearmedizin)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging — Thu, 17 Sep 2009 11:55:30 +0100

Conclusions A successful ablation is strongly dependent on the absorbed dose to the thyroid remnant. Dosimetry-based personalized treatment can prevent both sub-optimal administrations, which entails further radioiodine therapy, and excessive administration of radioactivity, which increases the potential for radiation toxicity. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-009-1261-3Authors Glenn D. Flux, Royal Marsden NHS Foundation Trust Department of Physics Downs Road Sutton Surrey SM2 5PT UKMasud Haq, Royal Marsden NHS Foundation Trust Thyroid Unit Downs Road Sutton Surrey SM2 5PT UKSarah J. Chittenden, Royal Marsden NHS Foundation Trust Department of Physics Downs Road Sutton Surrey SM2 5PT UKSusan Buckley, Royal Marsden NHS Foundation ...

Goitre and thyroid cancer

Medicine — Fri, 31 Jul 2009 11:53:28 +0100

Abstract: Thyroid enlargement is common and thyroid malignancy rare, but the clinical presentation of benign and malignant disease are similar. The aim of clinical assessment and investigations is to identify the small number of cancers amongst the non-malignant thyroid enlargements. Investigations include thyroid function tests and fine-needle aspiration cytology. Benign thyroid disease needs treatment only in the presence of dysfunction or local compressive symptoms. The treatment of thyroid cancer is multidisciplinary and includes surgery, radioiodine therapy and lifelong thyroid-stimulating hormone suppression. The diagnosis and management of thyroid cancer is being centralized around the multidisciplinary team in order to improve the outcomes in the UK. (Source: Medicine)

Construction of a MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for gene therapy of breast cancer

Breast Cancer Research — Sun, 26 Jul 2009 23:00:00 +0100

Conclusions: This construct may allow multimodal therapy, combining virotherapy with radioiodine therapy to be developed as a novel treatment for breast and other MUC1 overexpressing cancers. (Source: Breast Cancer Research)

Radiofrequency Ablation for the Treatment of Autonomously Functioning Thyroid Nodules

World Journal of Surgery — Mon, 06 Jul 2009 16:52:55 +0100

Conclusions RFA seems to be effective and safe for the treatment of AFTN. Content Type Journal ArticleDOI 10.1007/s00268-009-0130-3Authors Jung Hwan Baek, Thyroid Center, Daerim St. Mary’s Hospital Department of Radiology #978-13 Daerim-dong, Youngdeunpo-gu Seoul 150-070 KoreaWon-Jin Moon, Konkuk University Hospital, Konkuk University School of Medicine Department of Radiology 4-12 Hwayang-dong, Gwangjin-ku Seoul 143-729 KoreaYoon Suk Kim, Thyroid Center, Daerim St. Mary’s Hospital Department of Radiology #978-13 Daerim-dong, Youngdeunpo-gu Seoul 150-070 KoreaJeong Hyun Lee, University of Ulsan College of Medicine Department of Radiology Asan Medical Center, #388-1 Poongnap-2dong, Songpa-gu Seoul 138-736 KoreaDucky Lee, Thyroid Center, Daerim St. Mary’s Hospital D...

Radioiodine therapy of differentiated thyroid cancer: radiologic impact of out-patient treatment with 100 to 150 mCi Iodine-131 activities

Arquivos Brasileiros de Endocrinologia e Metabologia — Sun, 05 Jul 2009 10:55:22 +0100

CONCLUSIONS: No radiological impact was detected after iodine therapy with 100-150 mCi on an out-patient basis followed by experienced professionals. (Source: Arquivos Brasileiros de Endocrinologia e Metabologia)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Endogenous expression of the sodium iodide symporter mediates uptake of iodide in murine models of colorectal carcinoma

International Journal of Cancer — Mon, 29 Jun 2009 23:00:00 +0100

The sodium iodide symporter (NIS) mediates iodide uptake into the thyroid. Because of this mechanism, differentiated thyroid cancer is susceptible for radioiodine therapy. Functional NIS expression in extrathyroidal tumors has been reported mainly in breast cancer. We screened colorectal tumors for NIS expression and investigated the mechanisms regulating NIS activity. Cell lines were screened for iodide uptake in vitro and NIS expression was evaluated by real-time RT-PCR, immunocytochemistry and immunoblotting. Iodide and pertechnetate uptake were evaluated in allograft tumors by biodistribution studies and scintigraphy. Tumors of transgenic mouse models for colorectal cancer harboring mutations in the oncogenes KRAS, [beta]-catenin or the tumor-suppressor gene adenomatous-polyposis coli ...

Changing trends in the treatment of Graves' disease with radioiodine: a 12-year experience in a university hospital

Radiologia Brasileira — Thu, 25 Jun 2009 08:18:15 +0100

CONCLUSION: Radioiodine therapy has increasingly been accepted for treatment of patients with Graves' disease and the doses delivered have increased to achieve a permanent cure as well as a reduction of the chances of recurrence. (Source: Radiologia Brasileira)

Subjective perceptions of patients undergoing radioiodine therapy: why should we know about them?

European Journal of Nuclear Medicine and Molecular Imaging — Sat, 13 Jun 2009 08:37:43 +0100

Content Type Journal ArticleCategory EditorialDOI 10.1007/s00259-009-1188-8Authors Lutz S. Freudenberg, Universitätsklinikum Essen Klinik für Nuklearmedizin Hufelandstraße 55 45122 Essen GermanyStefan P. Müller, Universitätsklinikum Essen Klinik für Nuklearmedizin Hufelandstraße 55 45122 Essen GermanyAndreas Bockisch, Universitätsklinikum Essen Klinik für Nuklearmedizin Hufelandstraße 55 45122 Essen Germany Journal European Journal of Nuclear Medicine and Molecular ImagingOnline ISSN 1619-7089Print ISSN 1619-7070 (Source: European Journal of Nuclear Medicine and Molecular Imaging)

Subjective perceptions of patients undergoing radioiodine therapy: why should we know about them?

Nuklearmedizin — Fri, 12 Jun 2009 23:00:00 +0100

Authors: Freudenberg LS, Müller SP, Bockisch A PMID: 19526231 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)?

Oncology (Williston Park, N.Y.) — Sun, 31 May 2009 23:00:00 +0100

Authors: Mazzaferri EL The incidence of papillary thyroid cancer has been rising steadily over the past 3 decades. Most tumors in this setting are regarded as low risk, but recurrence rates are high, producing controversy about initial therapy. Microcarcinomas smaller than 1 cm are generally best treated with lobectomy alone. Total thyroidectomy should be performed for tumors 1 cm or larger or for tumors that have metastasized. Prophylactic central and lateral neck lymph node compartment dissection uncovers unsuspected metastases in about half the patients, which may alleviate the need for postsurgical radioiodine therapy but can be associated with surgical complications. Radioiodine may diminish tumor recurrence but is complicated by injury to nonthyroidal tissues and by dose-related ...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Synchronous papillary carcinoma in thyroglossal duct cyst and thyroid gland: Case report and review of literature

Head — Wed, 01 Apr 2009 04:00:00 +0100

We report a rare case of synchronous occurrence of thyroglossal duct cyst carcinoma and thyroid carcinoma and discuss its management in detail.A 59-year-old woman was clinically diagnosed to have a thyroglossal duct cyst and a solitary nodule. Fine-needle aspiration cytology revealed a papillary carcinoma in the thyroglossal duct cyst and a colloid in the thyroid nodule. Sistrunk's procedure along with a total thyroidectomy was performed followed by postoperative radioiodine ablation.Histopathologic examination revealed thyroglossal duct cyst carcinoma and bilateral foci of papillary carcinoma in the thyroid gland. She has remained free of disease on follow-up.Most cancers arising in thyroglossal duct cysts are of low risk, and Sistrunk's procedure is an adequate treatment for such cancers...

The relationship between 24 h/4 h radioiodine-131 uptake ratio and outcome after radioiodine therapy in 1402 patients with solitary autonomously functioning thyroid nodules

Annals of Nuclear Medicine — Thu, 26 Mar 2009 08:25:48 +0100

Conclusions The 131I UR can predict the outcome of 131I treatment in AFTN and may have utility in modifying treatment in some patients to limit post-radioiodine induced hypothyroidism and treatment failures in order to achieve euthyroidism. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s12149-009-0232-xAuthors Mauro Filesi, ‘La Sapienza’ University Department of Clinical Sciences, Nuclear Medicine, Policlinico Umberto I Viale del Policlinico 155 00161 Rome ItalyLaura Travascio, ‘La Sapienza’ University Department of Clinical Sciences, Nuclear Medicine, Policlinico Umberto I Viale del Policlinico 155 00161 Rome ItalyTeresa Montesano, ‘La Sapienza’ University Department of Clinical Sciences, Nuclear Medicine, Policlinico Umberto I Viale del...

[HEAD & NECK] The Role of MR Imaging in Detecting Nodal Disease in Thyroidectomy Patients with Rising Thyroglobulin Levels

American Journal of Neuroradiology — Wed, 11 Mar 2009 04:00:00 +0100

CONCLUSIONS: MR imaging of the neck should be considered in thyroidectomy patients with rising serum thyroglobulin levels and a history of radioiodine therapy and neck dissection. Radiologists should carefully examine the retropharyngeal and parapharyngeal spaces in these patients because nodal metastases may occur there more commonly than realized. (Source: American Journal of Neuroradiology)

A novel view on dosimetry-related radionuclide therapy: Presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging — Fri, 27 Feb 2009 13:51:41 +0100

Conclusion Redistribution of therapeutic activities along the model, i.e. taking into account success and risk, may enhance response while on average saving activity as exemplarily shown by a virtual comparison with standard approaches using literature data from DTC for implementation. The model may thus provide a guideline for the prescription of therapeutic activities; the results underline the potential impact of individual dosimetry in radionuclide therapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-009-1077-1Authors Alexander R. Stahl, University of Duisburg-Essen Clinic for Nuclear Medicine Hufelandstr. 55 45122 Essen GermanyLutz Freudenberg, University of Duisburg-Essen Clinic for Nuclear Medicine Hufelandstr. 55 45122 Essen German...

Radioiodine Therapy for Thyroid Cancer Depicted Uterine Leiomyoma.

Clinical Nuclear Medicine — Fri, 20 Feb 2009 18:36:55 +0100

Page: 180DOI: 10.1097/RLU.0b013e3181966ff0Authors: Hirata, Kenji MD *; Shiga, Tohru MD, PhD *; Kubota, Kanako C. MD +; Okamoto, Shozo MD *; Kamibayashi, Tomohito MD *; Tamaki, Nagara MD, PhD * (Source: Clinical Nuclear Medicine)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy.

Current Pharmaceutical Design — Wed, 21 Jan 2009 07:29:20 +0100

This article is going to show that molecular imaging probes in Nuclear Medicine can be regarded as proof of principle of many of recent trends in diagnosis and therapy and offers exciting opportunities for further developments. Radioiodine therapy of benign and malignant thyroid disease has been established in Nuclear Medicine over six decades ago and is a fine example for using the same highly specific probe for diagnosis and treatment of a given disease. The use of radio labeled monoclonal antibodies against surface receptors of tumor cells (e.g. CEA) dominated diagnostic Nuclear Medicine in the eighties and sees a recent revival in lymphoma treatment radioimmunotherapy. Finally Nuclear Medicine has shown that it may advance drug development by visualizing its biodistribution and site of...

Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines

European Journal of Nuclear Medicine and Molecular Imaging — Wed, 24 Dec 2008 08:51:11 +0100

Conclusion We hypothesize that testing of cells from primary tumours or metastases in patients may be a way to identify compounds with optimum therapeutic efficacy for individualized treatment. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-008-1024-6Authors Eleonore Fröhlich, University of Tuebingen Department of Endocrinology, Metabolism, Nephrology and Clinical Chemistry, Internal Medicine Otfried-Muellerstrasse 10 72076 Tuebingen GermanyPeter Brossart, University of Tuebingen Department of Haematology, Oncology, Immunology and Rheumatology, Internal Medicine Otfried-Muellerstrasse 10 72076 Tuebingen GermanyRichard Wahl, University of Tuebingen Department of Endocrinology, Metabolism, Nephrology and Clinical Chemistry, Internal Medicine Otf...

Radioiodine Therapy (RAI) for Graves' Disease (GD) and the Effect on Ophthalmopathy: A Systematic Review

Medscape Radiology Headlines — Tue, 23 Dec 2008 21:29:03 +0100

Does radioiodine therapy for Graves' disease, antithyroid drugs, or surgery raise the risk of ophthalmopathy? Does glucocorticoid prophylaxis effectively prevent ophthalmopathy occurrence/progression? Clinical Endocrinology (Source: Medscape Radiology Headlines)

Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.

European Journal of Clinical Investigation — Sat, 20 Dec 2008 08:23:27 +0100

Conclusions Simultaneous carbimazole reduces the euthyroidism rate, the aim of low-dose radioiodine therapy, over the entire target dose range in both Graves' disease and toxic nodular goitre. Therefore, antithyroid drug discontinuation should be preferred in low-dose radioiodine therapy. Conversely, escalation of the target dose should be preferred in high-dose radioiodine therapy. PMID: 19087129 [PubMed - in process] (Source: European Journal of Clinical Investigation)

Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance.

Nuklearmedizin — Sun, 07 Dec 2008 08:14:01 +0100

CONCLUSIONS: Relative uptake of subsequent radioiodine fractions decreases with time after first administration and with increasing delivered dose to the thyroid. If a second fraction of (131)I is given at an earlier time, the same therapeutic effect can be reached using lower amounts of activity, minimising radiation exposure and increasing efficiency of radioiodine therapy. PMID: 19057798 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

[Salivary gland damage after (131)I therapy in patient with differentiated thyroid cancer. Preliminary report.]

Endokrynologia Polska — Mon, 01 Dec 2008 16:15:09 +0100

Conclusions: The main conclusion is that a single dose of (131)I has no significant influence on salivary gland function; a repeated high-doses therapy is connected with an essential risk of side-effect occurrence. Scintigraphy can evaluate salivary gland function with high sensitivity. Parotid glands are more radiosensitive than submandibular. (Pol J Endocrinol 2008; 59 (5): 403-410). PMID: 18979451 [PubMed - as supplied by publisher] (Source: Endokrynologia Polska)

Diagnostic Whole-Body Scanning Before Radioiodine Therapy for Pulmonary Metastases of Differentiated Thyroid Cancer: Predictive Value and Recommendations.

Clinical Nuclear Medicine — Fri, 21 Nov 2008 08:14:41 +0100

Page: 845DOI: 10.1097/RLU.0b013e31818bf146Authors: Tachi, Yasushi MD *; Iwano, Shingo MD *; Kato, Katsuhiko MD *; Tadokoro, Masanori MD +; Naganawa, Shinji MD * (Source: Clinical Nuclear Medicine)

[Nuclear Medicine and Molecular Imaging] Incremental Value of Diagnostic 131I SPECT/CT Fusion Imaging in the Evaluation of Differentiated Thyroid Carcinoma

American Journal of Roentgenology — Wed, 19 Nov 2008 05:00:00 +0100

CONCLUSION. Iodine-131 SPECT/CT is useful for accurate evaluation of regional and distant activity in characterization of foci as residual thyroid tissue or nodal, pulmonary, or osseous metastasis. Suspected physiologic mimics of disease can be confirmed with increased reader confidence. (Source: American Journal of Roentgenology)

Thyroid cancer in infants and adolescents after Chernobyl.

Nuklearmedizin — Sat, 18 Oct 2008 09:56:59 +0100

Authors: Reiners C, Demidchik YE, Drozd VM, Biko J Studies in children medically exposed to external irradiation more than 50 years ago revealed a considerably increased risk for thyroid cancer. Similarly, a strongly age-dependent risk for thyroid cancer was observed in the Japanese population after the atomic bomb explosions with the highest risk in the group of children below age of 10. After the Chernobyl accident, children from Belarus living in highly exposed regions received mean thyroid doses by radioactive fallout higher by a factor of approximately 2 as compared to the survivors of the atomic bomb explosions. This lead to a radiation related increase of thyroid cancer incidence in children and adolescents with the highest incidence in age group 0-4 years up to now totally amou...

Relation between Graves' orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions.

Clinical Endocrinology — Wed, 10 Sep 2008 04:00:00 +0100

Authors: Tanda ML, Lai A, Bartalena L PMID: 18785990 [PubMed - as supplied by publisher] (Source: Clinical Endocrinology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Guidelines for radioiodine therapy of differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging — Fri, 01 Aug 2008 06:09:52 +0100

Discussion For this purpose, recommendations have been formulated based on recent literature and expert opinion regarding the rationale, indications and contraindications for these procedures, as well as the radioiodine activities and the administration and patient preparation techniques to be used. Recommendations also are provided on pre-RAIT history and examinations, patient counselling and precautions that should be associated with 131I iodine ablation and treatment. Furthermore, potential side effects of radioiodine therapy and alternate or additional treatments to this modality are reviewed. Appendices furnish information on dosimetry and post-therapy scintigraphy. Content Type Journal ArticleCategory GuidelinesDOI 10.1007/s00259-008-0883-1Authors M. Luster, U...

Recombinant human thyrotropin stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration.

The Journal of Clinical Endocrinology and Metabolism — Tue, 29 Jul 2008 04:00:00 +0100

Conclusion: On average, neither compression of the trachea nor deterioration of the pulmonary function was observed in the acute phase following rhTSH-augmented (131)I therapy. In the long term tracheal compression is diminished, and the inspiratory capacity improved, compared with (131)I therapy alone. PMID: 18664541 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Conventional withdrawal of thyroid hormone before radioiodine therapy in differentiated thyroid carcinoma: how frequently are adequately raised TSH levels attained?

Clinical Endocrinology — Wed, 18 Jun 2008 02:11:21 +0100

Clinical Endocrinology, Volume 69, Issue 1, Page 169-170, July 2008. (Source: Clinical Endocrinology)

Multiple Relapses of Hyperthyroidism after Thyroid Surgeries in a Patient with Long Term Follow-up of Sporadic Non-autoimmune Hyperthyroidism

Experimental and Clinical Endocrinology and Diabetes — Fri, 06 Jun 2008 16:26:18 +0100

We report on a 22 year old male patient who was treated for his multiple relapses of hyperthyroidism by repeated subtotal thyroidectomies (STE). During the 22 years of follow-up, the patient developed several relapses of hyperthyroidism, four of them after thyroid surgeries. Sequencing of the TSHR gene revealed a gain-of-function mutation with an amino acid exchange of aspartate to tyrosine in codon 633 which is located in the sixth transmembrane domain of the TSH receptor. The absence of the mutation in all other family members identifies the patient's TSHR mutation as a sporadic germline mutation. In this patient, thyroid tissue growth and hyperthyroidism could repeatedly be controlled only for limited periods by near total thyroidectomy. Therefore, this case confirms that early combined...

Survey of management of solitary thyroid nodules in Germany.

Nuklearmedizin — Thu, 22 May 2008 14:58:40 +0100

CONCLUSIONS: The main differences of opinion between practitioners and specialists focused on calcitonin screening and referral to radioiodine therapy. PMID: 18493687 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter

Endocrine — Tue, 20 May 2008 06:10:11 +0100

Abstract Radioiodine (131I) treatment for nontoxic and toxic multinodular goiter (MNG) is an alternative therapeutic procedure used especially for patients with contraindication for surgery. Several studies have been conducted in recent years assessing the use of recombinant human TSH (rhTSH) in increasing 131I uptake in MNGs. This procedure also decreases the activity level of the administered 131I, changes the distribution of 131I in the thyroid, lowers the absorption dose, and dramatically reduces the volume of the goiter (50–75% of the baseline volume). A major disadvantage, however, is the induction of hypothyroidism in a relatively large number of patients. A transient increase in thyroid volume and tenderness was noted in the first week of treatment. Also a short pe...

Graves' Disease and Thyroid Associated Ophthalmopathy following Radioiodine Therapy in Euthyroid Multinodular Goiter

Thyroid — Thu, 08 May 2008 17:01:40 +0100

Thyroid May 2008, Vol. 18, No. 5: 585-585. (Source: Thyroid)

[Is radioiodine therapy conducted too late in patients suffering from thyroid autonomy?]

Nuklearmedizin — Wed, 07 May 2008 21:11:40 +0100

CONCLUSION: Despite clear recommendations in corresponding guidelines too much time passes between first symptoms (median: 73 months), primary diagnosis of therapy relevant thyroid autonomy (median: 2 months) and implementation of RIT. Patients with functional and/or local symptoms should be examined for thyroid autonomy early. If thyroid autonomy is proven, RIT should be planned immediately, especially in high-risk patients. PMID: 18278206 [PubMed - indexed for MEDLINE] (Source: Nuklearmedizin)

[Radioiodine therapy in thyroid autonomy: initial results and experiences.]

Orvosi Hetilap — Sat, 26 Apr 2008 21:06:02 +0100

Conclusions: The results of radioiodine therapy in the analysed patient group are coherent with the data of several large studies. According to the references, the success rate of 85-100% are satisfying and the incidence of hypothyroidism of 10-20% is acceptable. PMID: 18436512 [PubMed - in process] (Source: Orvosi Hetilap)

Does radioiodine therapy for hyperthyroidism increase long-term morbidity?

Nature Clinical Practice Endocrinology and Metabolism — Tue, 04 Mar 2008 05:00:00 +0100

Authors: Burman KD PMID: 18317480 [PubMed - as supplied by publisher] (Source: Nature Clinical Practice Endocrinology and Metabolism)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

[Acute effects of radioiodine therapy on the voice and larynx of Basedow-Graves patients.]

Revista Brasileira de Otorrinolaringologia — Sat, 01 Mar 2008 05:00:00 +0100

CONCLUSION: Radioiodine therapy does not affect voice quality. PMID: 18568200 [PubMed - in process] (Source: Revista Brasileira de Otorrinolaringologia)

[Acute effects of radioiodine therapy on the voice and larynx of Basedow-Graves patients]

Revista Brasileira de Otorrinolaringologia — Sat, 01 Mar 2008 05:00:00 +0100

CONCLUSION: Radioiodine therapy does not affect voice quality. PMID: 18568200 [PubMed - in process] (Source: Revista Brasileira de Otorrinolaringologia)

[Influence of the endogene TSH stimulation of thyroid volume increase in the patients after total thyroidectomy due to differentiated thyroid cancer]

Endokrynologia Polska — Sat, 01 Mar 2008 05:00:00 +0100

CONCLUSIONS: L-Thyroxine withdrawal in the patients after total thyroidectomy due to DTC can cause re-growth of the tissue remnants. The phenomenon may be of a clinical significance in the selected cases influencing therapeutic decisions. PMID: 18465686 [PubMed - indexed for MEDLINE] (Source: Endokrynologia Polska)

Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?

Nuklearmedizin — Tue, 19 Feb 2008 20:43:20 +0100

CONCLUSION: To achieve a dose of over 200 Gy with the above standard deviation, we recommend calculating an intended dose of 250 Gy and using a dosimetric approach with early and late uptake values in the radioiodine test, to allow early therapeutic intervention should the posttherapeutic thyroid dose fall unexpectedly below 200 Gy. PMID: 18278207 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

Is radioiodine therapy conducted too late in patients suffering from thyroid autonomy?

Nuklearmedizin — Tue, 19 Feb 2008 20:43:20 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

The carcinogenic effects of radioiodine therapy for thyroid carcinoma.

Nature Clinical Practice Endocrinology and Metabolism — Tue, 19 Feb 2008 05:00:00 +0100

Authors: de Vathaire F PMID: 18283326 [PubMed - as supplied by publisher] (Source: Nature Clinical Practice Endocrinology and Metabolism)

Decreased radioiodine uptake of FRTL-5 cells after 131I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway

European Journal of Nuclear Medicine and Molecular Imaging — Tue, 29 Jan 2008 15:47:31 +0100

Conclusions It could be demonstrated that during 131I incubation of FRTL-5 cells, radioiodine uptake decreased significantly. Simultaneously decreasing levels of NIS mRNA and protein expression suggest a NIS-associated mechanism. Since mRNA levels of housekeeping genes decreased, too, the reduced NIS expression might be provoked by a cell cycle arrest. Our investigations recommend the FRTL-5 model as a valuable tool for further molecular biological investigations of the stunning phenomenon. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-007-0666-0Authors Birgit Meller, University of Lübeck Clinic of Radiology and Nuclear Medicine Ratzeburger Allee 160 23538 Lübeck GermanyErzsébet Gaspar, University of Lübeck Clinic of Internal Medicine I ...

Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer

Annals of Nuclear Medicine — Wed, 21 Nov 2007 16:42:24 +0100

The objective of this study was to report three cases with an accumulation of 131I in the nasolacrimal duct after radioiodine therapy for papillary thyroid cancer. A whole-body scan was taken 3 days after the administration of 3.7 GBq of 131I. Single-photon emission computed tomography (SPECT)/CT images were added when the location of a focal tracer uptake was undetermined on whole-body scans. In case 1, a 62-year-old woman complained of epiphora of the left eye after nine radioiodine therapies with a cumulative dose of 31.08 GBq. The left nasolacrimal duct was visualized at her tenth treatment with 131I. In case 2, a series of three radioiodine therapies had been given to a 73-year-old woman with a cumulative dose of 11.1 GBq. The accumulation of 131I was noted in the left nasol...

Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer

Strahlentherapie und Onkologie — Tue, 20 Nov 2007 15:30:06 +0100

Conclusion Parenchymal damage in salivary glands induced by high-dose radioiodine treatment can be reduced significantly by amifostine. This may help to increase patients’ quality of life in differentiated thyroid cancer. Content Type Journal ArticleCategory OriginalarbeitDOI 10.1007/BF02753843Authors Karl H. Bohuslavizki, University Hospital Eppendorf Department of Nuclear Medicine Martinistra\e 52 D-20246 HamburgSusanne Klutmann, University Hospital Eppendorf Department of Nuclear Medicine Martinistra\e 52 D-20246 HamburgChristian Bleckmann, University Hospital Eppendorf Department of Nuclear Medicine Martinistra\e 52 D-20246 HamburgWinfried Brenner, Christian Albrechts University of Kiel Clinic of Nuclear Medicine GermanyStefan Lassmann, Christian Albrechts Univer...

Cardiovascular assessment of hyperthyroid patients with multinodular goiter before and after radioiodine treatment preceded by stimulation with recombinant human TSH

Endocrine — Sat, 17 Nov 2007 23:21:04 +0100

In conclusion, rhTSH stimulated RAI treatment of MNG did not affect structural and functional parameters of the heart, despite transient high-serum levels of thyroid hormones. Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12020-007-9020-3Authors Maria Fernanda Barca, University of Sao Paulo Medical School Thyroid Unit, Division of Endocrinology, Department of Medicine Sao Paulo 01246-000 BrazilCesar Gruppi, University of Sao Paulo Medical School Instituto do Coração (INCOR) Sao Paulo 01246-000 BrazilMucio T. Oliveira, University of Sao Paulo Medical School Instituto do Coração (INCOR) Sao Paulo 01246-000 BrazilRossana Romão, University of Sao Paulo Medical School Thyroid Unit, Division of Endocrinology, Department of Medicine Sao Paulo 01246-000 BrazilMaria Si...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma

Clinical Endocrinology — Wed, 07 Nov 2007 02:39:07 +0100

Clinical Endocrinology, Volume 0, Issue 0, Page ???, December 2004. Summary Objective To evaluate the effects of pretreatment with the retinoid X receptor (RXR) agonist bexarotene on the efficacy of radioiodine therapy for metastases of differentiated thyroid carcinoma (DTC) with limited uptake of radioiodine (I-131). ... (Source: Clinical Endocrinology)

[Sodium iodide symporter in physiology and diseases -- the current state of knowledge]

Endokrynologia Polska — Thu, 01 Nov 2007 04:00:00 +0100

Authors: Wolny M, Syrenicz A The sodium iodide symporter, called also the NIS protein is responsible for iodine trapping to the cell what is significant for the thyroid function. Identified and described for the first time in 1996 NIS protein is the matter of interest of investigators concerning the thyroid physiology and pathology as well as others organs which concentrate the iodine. Existing studies on the sodium iodide symporter include among others: indicating NIS protein expression in the thyroid diseases and extrathyroidal tissues, studying of the NIS antygenicity in the autoimmune diseases of thyroid, finding the molecular aspects of the difference in the NIS protein activity. The sodium iodide symporter is a base of radioiodine therapy of, as for now, thyroid diseases only. Sh...

Procedure guideline for radioiodine therapy and (131)iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer.

Nuklearmedizin — Wed, 17 Oct 2007 14:06:13 +0100

Authors: Franzius C, Dietlein M, Biermann M, Frühwald M, Linden T, Bucsky P, Reiners C, Schober O The procedure guideline for radioiodine ((131)I) therapy and (131)I whole-body scintigraphy of differentiated thyroid cancer in paediatric patients is the counterpart to the procedure guidelines (version 3) for adult patients and specify the interdisciplinary guideline for thyroid cancer of the Deutsche Krebsgesellschaft concerning the nuclear medicine part. Characteristics of thyroid cancer in children are the higher aggressiveness of papillary thyroid cancer, the higher frequency of extrathyroidal extension and of disseminated pulmonary metastases as well as the high risk of local recurrences. Radioiodine therapy is generally recommended in children, the (131)I activity depends on t...

Guideline for radioiodine therapy for benign thyroid diseases (version 4).

Nuklearmedizin — Wed, 17 Oct 2007 14:06:13 +0100

Authors: Dietlein M, Dressler J, Grünwald F, Leisner B, Moser E, Reiners C, Schicha H, Schneider P, Schober O Version 4 of the guideline for radioiodine therapy for benign thyroid diseases includes an interdisciplinary consensus on decision making for antithyroid drugs, surgical treatment and radioiodine therapy. The quantitative description of a specific goiter volume for radioiodine therapy or operation was cancelled. For patients with nodular goiter with or without autonomy, manifold circumstances are in favor of surgery (suspicion on malignancy, large cystic nodules, mediastinal goiter, severe compression of the trachea) or in favor of radioiodine therapy (treatment of autonomy, age of patient, co-morbidity, history of prior subtotal thyroidectomy, profession like teacher, spe...

Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3).

Nuklearmedizin — Wed, 17 Oct 2007 14:06:13 +0100

Authors: Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B, Luster M, Moser E, Reiners C, Schicha H, Schober O The procedure guideline for radioiodine therapy (RIT) of differentiated thyroid cancer (version 3) is the counterpart to the procedure guideline for (131)I whole-body scintigraphy (version 3) and specify the interdisciplinary guideline for thyroid cancer of the Deutsche Krebsgesellschaft concerning the nuclear medicine part. Recommendation for ablative (131)I therapy is given for all differentiated thyroid carcinoma (DTC) >1 cm. Regarding DTC </=1 cm (131)I ablation may be helpful in an individual constellation. Preparation for (131)I ablation requires low iodine diet for two weeks and TSH-stimulation by withdrawal of thyroid hormone medication or...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3).

Nuklearmedizin — Wed, 17 Oct 2007 14:06:13 +0100

Authors: Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B, Luster M, Reiners C, Schicha H, Schober O Version 3 of the procedure guideline for (131)I whole-body scintigraphy (WBS) is the counterpart to the procedure guideline for radioiodine therapy (version 3) and specify the interdisciplinary guideline for thyroid cancer of the Deutsche Krebsgesellschaft concerning the nuclear medicine part. (131)I WBS 3-6 months after (131)I ablation remains a standard procedure in an endemic area for thyroid nodules and the high frequency of subtotal surgical procedures. Follow-up without (131)I WBS is only justified if the following preconditions are fulfilled: low-risk group pT1-2, pN0 M0 with histopathologically confirmed pN0, (131)I uptake <2%, (131)I WBS during ablat...

Image-Guided Radioiodide Therapy of Medullary Thyroid Cancer After Carcinoembryonic Antigen Promoter-Targeted Sodium Iodide Symporter Gene Expression

Human Gene Therapy — Thu, 11 Oct 2007 14:24:58 +0100

Human Gene Therapy , Vol. 0, No. 0: 916-924. In contrast to follicular cell-derived thyroid cancer, medullary thyroid cancer (MTC) remains difficult to treat because of its unresponsiveness to radioiodine therapy, or to conventional chemo- and radiotherapy. We therefore examined the feasibility of ... (Source: Human Gene Therapy)

Predictors of radioiodine therapy success in Graves' disease identified

AuntMinnie.com Headlines — Wed, 10 Oct 2007 16:40:14 +0100

NEW YORK (Reuters Health), Oct 10 - Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease, two researchers from Croatia report in the September issue of the Journal of Clinical Endocrinology and Metabolism. The clinicians tested their hypothesis in a group of 177 patients with Graves' disease who underwent radioiodine therapy and were followed up one year after treatment. (Source: AuntMinnie.com Headlines)

Predictors of Radioiodine Therapy Success in Graves' Disease Identified

Medscape Radiology Headlines — Wed, 10 Oct 2007 15:39:08 +0100

Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease, two researchers from Croatia report in the September issue of the Journal of Clinical Endocrinology and Metabolism. Reuters Health Information (Source: Medscape Radiology Headlines)

Radioiodine Therapy after Pre-treatment with Bexarotene for Metastases of Differentiated Thyroid Carcinoma

Clinical Endocrinology — Mon, 08 Oct 2007 17:52:32 +0100

Clinical Endocrinology Volume 0, Issue ja. Abstract Objective: To evaluate the effects of pre-treatment with the Retinoid X Receptor (RXR) agonist bexarotene on the efficacy of radioiodine therapy of metastases of differentiated thyroid carcinoma (DTC) with limited uptake of radioiodine (I-131). D... (Source: Clinical Endocrinology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases.

Haematologica — Sat, 01 Sep 2007 04:00:00 +0100

Authors: Focosi D, Galimberti S, Petrini M PMID: 17768141 [PubMed - in process] (Source: Haematologica)

Do antithyroid drugs influence outcome after radioiodine therapy for hyperthyroidism?

Nature Clinical Practice Endocrinology and Metabolism — Sat, 01 Sep 2007 04:00:00 +0100

Authors: Razvi S, Pearce SH PMID: 17637723 [PubMed - in process] (Source: Nature Clinical Practice Endocrinology and Metabolism)

[The importance of bisoprolol in prevention of heart left ventricular hypertrophy in patients with long term L-thyroxin suppressive therapy, after the operation of differentiated thyroid carcinoma]

Endokrynologia Polska — Sat, 01 Sep 2007 04:00:00 +0100

CONCLUSIONS: 1. In differentiated thyroid cancer patients, treated postoperatively with L-thyroxine suppressive therapy, left ventricular hypertrophy is observed already during the first year of suppressive therapy and progresses during the next year of treatment. 2 Addition of a beta-adrenergic antagonist to suppressive doses of L-thyroxine causes a regression of left ventricular hypertrophy, thus, beta-adrenergic antagonists should be administered in this group of patients. PMID: 18058733 [PubMed - indexed for MEDLINE] (Source: Endokrynologia Polska)

Airway complication occurring during radioiodine treatment for Graves' disease

Annals of Nuclear Medicine — Sat, 18 Aug 2007 06:48:29 +0100

This study presents two cases in which 131I therapy caused this acute complication. The patients complained of the symptom 6 h and 33 h after administration of 131I. A histamine H1 receptor antagonist and hydrocortisone rapidly resolved symptoms in both cases. These two cases remind physicians that 131I therapy for Graves' disease may cause potentially life-threatening complications. Content TypeJournal Article JournalAnnals of Nuclear MedicineOnline ISSN 1864-6433Print ISSN 0914-7187 Journal VolumeVolume 21 Journal IssueVolume 21, Number 6 / August, 2007 (Source: Annals of Nuclear Medicine)

Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?

Nuklearmedizin — Sun, 17 Jun 2007 05:45:20 +0100

CONCLUSION: The administration of 600 microg inactive iodide for three days during radioiodine therapy in patients with Graves' hyperthyroidism and an unexpectedly short half-life of <3 or 4 days was a safe and effective alternative to the administration of a second radioiodine capsule. PMID: 17549318 [PubMed - in process] (Source: Nuklearmedizin)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Management of multinodular goiter in Germany (Papillon 2005): do the approaches of thyroid specialists and primary care practitioners differ?

Nuklearmedizin — Sun, 17 Jun 2007 05:45:20 +0100

CONCLUSIONS: Treatment and diagnostic procedures are used to nearly the same extent in primary care and specialist institutions, but the opinions diverge over the issues of calcitonin screening and referral for radioiodine therapy. PMID: 17549317 [PubMed - in process] (Source: Nuklearmedizin)

Recent advances in treatment of medullary thyroid carcinoma.

Annales d'Endocrinologie — Fri, 01 Jun 2007 04:00:00 +0100

Authors: Vezzosi D, Bennet A, Caron P Medullary thyroid carcinoma accounts for 5-10% of all thyroid cancers. It is sporadic in 75% of cases and familial in 25% of cases. Germ-line REarranged during transfection (RET) proto-oncogene mutations are detected in more than 95% of patients with familial medullary carcinoma whereas somatic RET mutations are detected in 40-70% of sporadic medullary carcinomas. Surgery is the only curative treatment and should consist of total thyroidectomy with central and ipsilateral or bilateral lateral lymph node dissection. Surgery provides successful cure in almost 100% of patients when tumor size measures a few millimeters, in almost 90% of patients with a tumor measuring less than 1 cm, and in only 50% of patients with a tumor larger than 1 cm. Alternati...

Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy

Radiation Protection Dosimetry — Thu, 24 May 2007 04:00:00 +0100

On 27 occasions, radiation doses were measured for a family member designated as the ‘caregiver’ for a patient receiving high-dose radioiodine outpatient therapy for differentiated thyroid carcinoma. For 25 of the administrations, patients received 3.7 GBq of 131I. Radiation doses for the designated caregivers were monitored on an hourly basis for 1 week using electronic personal dosemeters. The average penetrating dose was 98 ± 64 µSv. The maximum penetrating dose was 283 µSv. Measured dose rate profiles showed that, on average, one-third of the caregiver dose was received during the journey home from hospital. The mean dose rate profile showed rapid clearance of 131I with three distinct phases. The corresponding clearance half-times were <1 h, 21 h and ~...

Pediatric thyroid cancer arising after treatment for pleuropulmonary blastoma

Pediatric Blood and Cancer — Fri, 18 May 2007 04:00:00 +0100

A 3-year-old female presented with a large tumor occupying the right thoracic space. Open biopsy revealed the pathological diagnosis of pleuropulmonary blastoma. After the first-line chemotherapy, the patient underwent surgical resection, then two courses of high-dose chemotherapy. Three years later, follicular carcinoma of the right thyroid lobe was found, so a right hemithyroidectomy was performed. Five months later, the thyroid tumor recurred. The remaining thyroid lobe was completely excised and radioiodine therapy was administered. The patient has remained tumor-free for 3 years. The etiology and treatment of the uncommon combination of pleuropulmonary blastoma and thyroid carcinoma is discussed. Pediatr Blood Cancer © 2007 Wiley-Liss, Inc. (Source: Pediatric Blood and Cancer)

Surgery versus Radioiodine Therapy as Definitive Management for Graves' Disease: The Role of Patient Preference

Thyroid — Thu, 22 Feb 2007 16:13:08 +0100

Thyroid Feb 2007, Vol. 17, No. 2: 157-160. (Source: Thyroid)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably benign thyroid disease

Journal of Postgraduate Medicine — Sat, 10 Feb 2007 23:50:05 +0100

Conclusions: PTMC is not an uncommon incidental finding after surgery for presumably benign thyroid disease (7.1% in our series). The possibility of an underlying PTMC should be taken into account in the management of patients with nodular thyroid disease; total/near total thyroidectomy should be considered, at least in selected patients with presumably benign nodular thyroid disease. (Source: Journal of Postgraduate Medicine)

Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay.

Nuclear Medicine Communications — Mon, 22 Jan 2007 12:40:02 +0100

(Source: Nuclear Medicine Communications)

[Evil radioactivity. Subjective perception of radioactivity in patients with thyroid disease prior to treatment with radioiodine]

Nuklearmedizin — Sat, 06 Jan 2007 17:43:02 +0100

CONCLUSIONS: Knowing about significant differences in patient's perception about radioactivity in general or in the clinical context may help to optimise and tailor the initial, pre-therapeutical interview towards the patient. PMID: 17043735 [PubMed - indexed for MEDLINE] (Source: Nuklearmedizin)

Recombinant Human Thyrotropin-Assisted Radioiodine Therapy for Patients with Metastatic Thyroid Cancer Who Could Not Elevate Endogenous Thyrotropin or Be Withdrawn from Thyroxine

Thyroid — Fri, 24 Nov 2006 12:10:12 +0100

Thyroid Nov 2006, Vol. 16, No. 11: 1121-1130. (Source: Thyroid)

Evil radioactivity. Subjective perception of radioactivity in patients with thyroid disease prior to treatment with radioiodine.

Nuklearmedizin — Thu, 19 Oct 2006 12:35:02 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not?

Nuklearmedizin — Thu, 19 Oct 2006 12:35:02 +0100

CONCLUSION: Using lithium as adjunct to radioiodine therapy increases the radiation dose delivered to the thyroid by 39% on average and nearly 30% of radioiodine activity can be saved in these patients. Lithium is recommended in patients with very short effective half-life in the diagnostic test in order to reduce the activity required and whole-body radiation dose. PMID: 17043732 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

What is the best pre-therapeutic dosimetry for successful radioiodine therapy of multifocal autonomy?

Nuklearmedizin — Thu, 19 Oct 2006 12:35:02 +0100

CONCLUSIONS: TcTUsbased determination of the autonomous volume should not be performed, the TcTUs-based adaptation of the target dose will only increase the rate of hypothyroidism. A standard half-life may be used in pre-therapeutic dosimetry for RIT of MFA. If so, individual therapeutic activities may be calculated based on thyroid size corrected to the 24h ITUs without using Marinelli's algorithm. PMID: 17043731 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

Skull metastasis from papillary thyroid carcinoma accompanied by neurofibromatosis type 1 and pheochromocytoma: report of a case

Brain Tumor Pathology — Thu, 19 Oct 2006 07:54:29 +0100

We report here a 74-year-old woman with a skull metastasis from papillary thyroid carcinoma (PTC). In her medical history, she was diagnosed with neurofibromatosis type 1 (NF1) at age 28 years, and she underwent thyroidectomy for PTC at age 52 years and adrenectomy for pheochromocytoma (PC) at age 58 years. She was admitted to our hospital with an increased mass in the forehead. Head computed tomography (CT) showed an expansive, osteolytic, and solid tumor extending from the dura mater into the subcutis, destroying part of the frontal bone. Head magnetic resonance imaging (MRI) revealed that the tumor was chiefly extradural but partially invaded the dura mater. Cerebral angiography showed that the tumor was fed from a branch of the external carotid artery. She underwent surgery, and ...

Patients Receiving Treatment With Radioisotopes May Trigger Security Alarms

Radiology / Nuclear Medicine News From Medical News Today — Mon, 07 Aug 2006 21:00:00 +0100

Patients receiving treatment with radioisotopes should be warned that they may trigger radiation alarms, say doctors in the BMJ.Their advice follows the case of a patient who activated an airport radiation detector six weeks after receiacving radioiodine therapy. He was detained and subjected to extensive search and questioning. Luckily he was carrying his treatment card with him and was released after a prolonged delay and considerable embarrassment. [click link for full article] (Source: Radiology / Nuclear Medicine News From Medical News Today)

Patients Receiving Treatment With Radioisotopes May Trigger Security Alarms

ScienceDaily Headlines — Sat, 05 Aug 2006 20:18:01 +0100

Patients receiving treatment with radioisotopes should be warned that they may trigger radiation alarms, say doctors in this week's BMJ. Their advice follows the case of a patient who activated an airport radiation detector six weeks after receiving radioiodine therapy. He was detained and subjected to extensive search and questioning. Luckily he was carrying his treatment card with him and was released after a prolonged delay and considerable embarrassment. (Source: ScienceDaily Headlines)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy

Internal Medicine Journal — Thu, 03 Aug 2006 14:14:16 +0100

Internal Medicine Journal Volume 36, Issue 9, Page 564-570, Sep 2006. (Source: Internal Medicine Journal)

DTB reviews radioiodine therapy for hyperthyroidism

NeLM Headline News — Wed, 07 Jun 2006 00:00:00 +0100

The Drug and Therapeutics Bulletin (DTB) has reviewed radioiodine therapy for adults with hyperthyroidism. The review compares radioiodine therapy with antithyroid drugs, surgery and other therapies for hyperthyroidism. (Source: NeLM Headline News)

Thyroid nodule: a potentially malignant lesion; optimal management from a surgical perspective.

Cancer Treatment Reviews — Mon, 01 May 2006 04:00:00 +0100

Authors: Sakorafas GH, Peros G Thyroid nodules are very common lesions, frequently detected by modern imaging methods (mainly ultrasonography). Despite that most thyroid nodules represent benign lesions, a small but significant percentage of them are malignant. Surgery is indicated when there is underlying malignancy (or suspicion for), pressure symptoms, or for cosmetic reasons. Total/near total thyroidectomy is the most radical procedure, which achieves cure, avoids the possibility of reoperation in the future (completion thyroidectomy), and facilitates postoperative management of the patient with underlying malignancy. Simple observation and thyroid hormone suppressive therapy are acceptable management options for patients with presumably benign thyroid nodules. Radioiodine therapy ...

Radioiodine therapy in hyperthyroid disease: poorer outcome in patients with high 24 hours radioiodine uptake

Clinical Physiology and Functional Imaging — Tue, 25 Apr 2006 16:20:56 +0100

Clinical Physiology and Functional Imaging Volume 26, Issue 3, Page 167-170, May 2006 (Source: Clinical Physiology and Functional Imaging)

Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies

Clinical Endocrinology — Wed, 12 Apr 2006 12:46:03 +0100

Clinical Endocrinology Volume 64, Issue 6, Page 617-624, Jun 2006 (Source: Clinical Endocrinology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer

Oral Diseases — Tue, 28 Feb 2006 09:04:13 +0100

Oral Diseases Volume 12, Issue 3, Page 297-300, May 2006 (Source: Oral Diseases)

Hypothyroid symptoms following radioiodine therapy for Graves' disease.

Clinical Cornerstone — Sat, 01 Jan 2005 05:00:00 +0100

Authors: Anolik JR PMID: 16399243 [PubMed - indexed for MEDLINE] (Source: Clinical Cornerstone)